Free guide
The GLP-1 exit plan: surviving the 12-month window.
Intensive weight treatment ends. The biology that drove your loss withdraws. Here's what the published research says happens next — and the four-step plan for keeping the result.
What the research shows
The window is real, and it's measurable.
In a controlled trial, people who stopped weekly semaglutide regained about two-thirds of the weight they had lost within twelve months (Rubino et al., JAMA 2022). Most of that regain happened in the first six months.
This isn't a willpower problem. A year after weight loss, appetite-stimulating hormones remain roughly twice their pre-diet baseline (Sumithran et al., NEJM 2011), and resting metabolic rate stays suppressed for years (Fothergill et al., Obesity 2016). The body actively campaigns to restore the old weight.
And the exit is common: most people on injectable therapy discontinue by one year (Wilding et al., Diabetes Obes Metab 2023) — usually without any structured plan for what comes next.
The plan
Four steps for the window.
01.
Plan the taper with your clinician
If you're on an injectable, the exit should be a decision you make with the prescriber — timing, dose steps, and what to watch. Never stop abruptly on your own.
02.
Put structured appetite support in place first
Hunger hormones stay elevated long after the loss phase. Whatever your support looks like — protein-forward meals, scheduled eating, appetite support like Phase 02 — have it running before the last dose, not after.
03.
Protect metabolic stability
Resting metabolic rate stays suppressed after sustained loss. Resistance training two to three times a week and adequate protein are the best-evidenced counters. Consistency beats intensity.
04.
Track the window, not the day
Most regain happens in the first six months and continues to twelve. Weigh weekly, act on the trend — a two-week upward drift is a signal to tighten the system, not a failure.
This guide is educational, not medical advice. Decisions about starting or stopping any medication belong with you and your healthcare professional.
Where Oprimaze fits.
Phase 02 — Weight Maintenance was designed for exactly this window: a daily nasal spray whose active is a hemp-derived cannabinoid blend (THCV, CBD & CBC) for appetite and metabolic support — non-intoxicating, contains no THC (the active is THCV, not THC), non-detectable on standard drug screens, and backed by our own 100-person consumer study. No needles, no prescription barrier.
Want this guide in your inbox?
We'll send it over, plus a short series on making the window work.